DE602006015103D1 - Als medikament geeignete lösliche varianten des gp130-moleküls - Google Patents

Als medikament geeignete lösliche varianten des gp130-moleküls

Info

Publication number
DE602006015103D1
DE602006015103D1 DE602006015103T DE602006015103T DE602006015103D1 DE 602006015103 D1 DE602006015103 D1 DE 602006015103D1 DE 602006015103 T DE602006015103 T DE 602006015103T DE 602006015103 T DE602006015103 T DE 602006015103T DE 602006015103 D1 DE602006015103 D1 DE 602006015103D1
Authority
DE
Germany
Prior art keywords
soluble
medicament
soluble variants
molecular
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006015103T
Other languages
English (en)
Inventor
Dirk Seegert
Georg H Waetzig
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Conaris Research Institute AG
Original Assignee
Conaris Research Institute AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Conaris Research Institute AG filed Critical Conaris Research Institute AG
Publication of DE602006015103D1 publication Critical patent/DE602006015103D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
DE602006015103T 2005-12-23 2006-12-22 Als medikament geeignete lösliche varianten des gp130-moleküls Active DE602006015103D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05028420A EP1801121A1 (de) 2005-12-23 2005-12-23 Lösliche Varianten des Moleküls gp130 nützlich als Arzneimittel
PCT/EP2006/012515 WO2007071449A1 (en) 2005-12-23 2006-12-22 Soluble gp130 molecule variants useful as a medicament

Publications (1)

Publication Number Publication Date
DE602006015103D1 true DE602006015103D1 (de) 2010-08-05

Family

ID=36233865

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006015103T Active DE602006015103D1 (de) 2005-12-23 2006-12-22 Als medikament geeignete lösliche varianten des gp130-moleküls

Country Status (9)

Country Link
US (1) US7851182B2 (de)
EP (2) EP1801121A1 (de)
JP (1) JP5390191B2 (de)
AT (1) ATE471945T1 (de)
AU (1) AU2006328909A1 (de)
CA (1) CA2633213A1 (de)
DE (1) DE602006015103D1 (de)
ES (1) ES2347694T3 (de)
WO (1) WO2007071449A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1873166E (pt) 2006-06-30 2010-12-09 Conaris Res Inst Ag Dímeros de sgp130fc melhorados
WO2009014263A1 (ja) * 2007-07-26 2009-01-29 Osaka University インターロイキン６受容体阻害剤を有効成分とする眼炎症疾患治療剤
EP2050759A1 (de) * 2007-10-19 2009-04-22 CONARIS research institute AG Lösliche gp-130-Muteine mit verbesserter Bindungsaktivität
PL3226888T3 (pl) 2014-12-01 2021-11-02 Ferring B.V. Podawanie selektywnego transsygnałowego inhibitora IL-6
MA41116A (fr) 2014-12-01 2017-10-10 Ferring Bv Compositions d'inhibiteur de trans-signalisation par l'il-6 sélectif
WO2017106244A1 (en) * 2015-12-14 2017-06-22 The Trustees Of The University Of Pennsylvania Compositions and methods for regulatable antibody expression

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994012520A1 (en) * 1992-11-20 1994-06-09 Enzon, Inc. Linker for linked fusion polypeptides
AU778998B2 (en) * 1998-09-22 2004-12-23 University Of Maryland At Baltimore Cystine knot growth factor mutants
JP2002534962A (ja) * 1999-01-07 2002-10-22 レキシジェン ファーマシューティカルズ コーポレイション Ｆｃ融合タンパク質としての抗肥満症タンパク質の発現および輸送
SI1148065T1 (sl) * 2000-04-21 2008-06-30 Conaris Res Inst Ag FUZIJSKI PROTEINI, KI VSEBUJEJO DVE TOPNI MOLEKULI gp130.
DE60224822T2 (de) * 2001-10-19 2009-01-22 Zymogenetics, Inc., Seattle Dimerisierter wachstumsfaktor sowie materialien und verfahren zu seiner herstellung
EP1491554A1 (de) * 2003-06-23 2004-12-29 CONARIS research institute AG PEGlierte lösliche gp130-Dimeren geignet als Medikament
JP2008504012A (ja) * 2004-01-28 2008-02-14 シントニックス・ファーマシューティカルズ・インコーポレーテッド 不妊治療のためのへテロ二量体卵胞刺激ホルモン−Ｆｃ（ＦＳＨ−Ｆｃ）融合タンパク質

Also Published As

Publication number Publication date
JP5390191B2 (ja) 2014-01-15
EP1801121A1 (de) 2007-06-27
US7851182B2 (en) 2010-12-14
JP2009520480A (ja) 2009-05-28
EP1994053B1 (de) 2010-06-23
CA2633213A1 (en) 2007-06-28
ES2347694T3 (es) 2010-11-03
US20090227499A1 (en) 2009-09-10
ATE471945T1 (de) 2010-07-15
AU2006328909A1 (en) 2007-06-28
EP1994053A1 (de) 2008-11-26
WO2007071449A1 (en) 2007-06-28

Similar Documents

Publication Publication Date Title
DE602006015103D1 (de) Als medikament geeignete lösliche varianten des gp130-moleküls
UA117216C2 (uk) Пухлиноасоційований пептид та його застосування
Bai et al. Improving the oral efficacy of recombinant granulocyte colony-stimulating factor and transferrin fusion protein by spacer optimization
Lansdell et al. Palau’amine and related oroidin alkaloids dibromophakellin and dibromophakellstatin inhibit the human 20S proteasome
EA200801460A1 (ru) Рекомбинантные моновалентные антитела и способы их получения
ATE473759T1 (de) Bifunktionelle moleküle sowie darauf basierende therapien.
EA200801166A1 (ru) Форматы конкурентного доменного антитела, которые связываются с рецептором интерлейкина 1 первого типа
MEP53308A (en) Novel peptides that bind to the erythropoietin receptor
JP2012522529A5 (de)
JP2008500025A5 (de)
CA2818990A1 (en) Designed repeat proteins binding to serum albumin
RU2010137743A (ru) Конъюгированные молекулы фактора viii
DE602007004120D1 (de) Spezifische monokonjugate von g-csf
CO6390070A2 (es) Terapeuticos dirigidos a base de proteinas manipuladas para receptores de tirosina cinasas incluyendo receptor de factor de crecimiento tipo insulina -i
RU2014143639A (ru) Регулируемые протеазой антитела
Suzuki et al. Syndecan binding sites in the laminin α1 chain G domain
EA200700213A1 (ru) Терапевтические композиции с нейротоксином ботулина
EP2537533A3 (de) Mittels indirekter chemischer Konjugation erhaltene Antitumor-Biokonjugate von Hyaluronsäure oder Derivaten davon
Chang et al. An updated review of smac mimetics, LCL161, birinapant, and GDC-0152 in cancer treatment
BRPI0517843A (pt) compostos de moléculas conjugadas com a atividade de absorção de células aumentada
CY1120436T1 (el) Αντιανδρογονα πεπτιδια και χρησεις αυτων στη θεραπεια του καρκινου
Cai et al. Metal-assisted assembly and stabilization of collagen-like triple helices
WO2006097327A3 (en) Soluble btnl2 protein useful to inhibit inflammatory disorders
ATE491044T1 (de) Gene und polypeptide in verbindung mit brustkrebserkrankungen
BRPI0407031A (pt) Composições e métodos para tratamento de câncer empregando igsf9 e liv-1